Literature DB >> 22740754

Extensive myocardial iron deposition in a patient with hepatitis C.

Arthur Rusovici1, Samia Ibrahim, Sunita Sood, James Maher, Christine Gerula, Edo Kaluski, Marc Klapholz.   

Abstract

During a cardiac evaluation prior to liver transplantation, a 51-year-old man with hepatitis C and cirrhosis was found to have nonischemic cardiomyopathy-a condition that would have made him ineligible for liver transplantation. Right ventricular biopsy revealed extensive cardiac hemosiderosis. Despite the elevated levels of serum ferritin, the patient had no history of multiple red blood cell transfusions; moreover, genetic testing for hereditary hemochromatosis was negative for the HFE mutations C282Y and H63D. Chelation therapy was considered for this patient, to reduce the cardiac iron deposits. However, before a course of treatment was established, the patient's clinical condition worsened, and chelation therapy was no longer feasible. He was referred for combined heart and liver transplantation. Cardiac iron deposition can be diagnosed readily using right ventricular biopsy or T2* magnetic resonance imaging. Early detection may allow time for intensive chelation therapy, which might, in turn, reverse the myopathic process. Improved cardiac function should improve cirrhosis patients' chances to be placed on the liver transplant waiting list and ultimately optimize transplantation outcomes.

Entities:  

Keywords:  Cardiac hemosiderosis; T2* magnetic resonance imaging; cardiomyopathy; chelation therapy; cirrhosis; hepatitis C; iron overload; iron/metabolism; liver transplantation

Mesh:

Substances:

Year:  2012        PMID: 22740754      PMCID: PMC3384049     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  11 in total

1.  Iron chelating in thalassaemia with left ventricular dysfunction.

Authors:  G Cagirci; O Tufekcioglu; M Yetim
Journal:  Heart       Date:  2006-10       Impact factor: 5.994

2.  A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.

Authors:  M A Tanner; R Galanello; C Dessi; G C Smith; M A Westwood; A Agus; M Roughton; R Assomull; S V Nair; J M Walker; D J Pennell
Journal:  Circulation       Date:  2007-03-19       Impact factor: 29.690

Review 3.  Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease.

Authors:  S Møller; J H Henriksen
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

4.  Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH).

Authors:  Giovanna Fabio; Francesca Minonzio; Paola Delbini; Annamaria Bianchi; Maria Domenica Cappellini
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

5.  Cirrhotic cardiomyopathy.

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2008-11-11       Impact factor: 6.047

6.  Hepatic iron overload in alcoholic end-stage liver disease is associated with iron deposition in other organs in the absence of HFE-1 hemochromatosis.

Authors:  Sue C Eng; Shari L Taylor; Victoria Reyes; Stuart Raaka; Jose Berger; Kris V Kowdley
Journal:  Liver Int       Date:  2005-06       Impact factor: 5.828

Review 7.  Cirrhotic cardiomyopathy.

Authors:  Saleh A Alqahtani; Tamer R Fouad; Samuel S Lee
Journal:  Semin Liver Dis       Date:  2008-02       Impact factor: 6.115

8.  Marked iron in liver explants in the absence of major hereditary hemochromatosis gene defects: a risk factor for cardiac failure.

Authors:  Hubert Fenton; Michael Torbenson; Perumal Vivekanandan; Matthew M Yeh; John Hart; Linda Ferrell
Journal:  Transplantation       Date:  2009-04-27       Impact factor: 4.939

9.  Hepatic siderosis in extrahepatic portal vein obstruction. Role of spontaneous portosystemic shunting?

Authors:  J P Capron; A Remond; J L Dupas; H Mancheron; D Capron-Chivrac; A Brailon
Journal:  Dig Dis Sci       Date:  1986-08       Impact factor: 3.199

10.  Postshunt hemochromatosis leading to cardiogenic shock in a patient presenting for orthotopic liver transplant: a case report.

Authors:  C G Hughes; J M Waldman; J Barrios; A Robertson
Journal:  Transplant Proc       Date:  2009-06       Impact factor: 1.066

View more
  1 in total

1.  The role of S-methylisothiourea hemisulfate as inducible nitric oxide synthase inhibitor against kidney iron deposition in iron overload rats.

Authors:  Maryam Maleki; Melika Samadi; Mehrangiz Khanmoradi; Mehdi Nematbakhsh; Ardeshir Talebi; Hamid Nasri
Journal:  Adv Biomed Res       Date:  2016-05-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.